Literature DB >> 21373381

Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance.

Jill M Kolesar1, Kamakshi Sachidanandam, William R Schelman, Jens Eickhoff, Kyle D Holen, Anne M Traynor, Dona B Alberti, James P Thomas, Christopher R Chitambar, George Wilding, William E Antholine.   

Abstract

PURPOSE: 3-AP (3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP) is a metal chelator that potently inhibits the enzyme ribonucleotide reductase, RR, which plays a key role in cell division and tumor progression. A sub-unit of RR has a non-heme iron and a tyrosine free radical, which are required for the enzymatic reduction of ribonucleotides to deoxyribonucleotides. The objective of the study was to determine whether 3-AP affects its targeted action by measuring EPR signals formed either directly or indirectly from low molecular weight ferric-3-AP chelates.
METHODS: Peripheral blood lymphocytes were collected from patients with refractory solid tumors at baseline and at 2, 4.5 and 22 hours after 3-AP administration. EPR spectra were used to identify signals from high-spin Fe-transferrin, high-spin heme and low-spin iron or copper ions.
RESULTS: An increase in Fe-transferrin signal was observed, suggesting blockage of Fe uptake. It is hypothesized that formation of reactive oxygen species by FeT(2) or CuT damage transferrin or the transferrin receptor. An increase in heme signal was also observed, which is a probable source of cytochrome c release from the mitochondria and potential apoptosis. In addition, increased levels of Fe and Cu were identified.
CONCLUSION: These results, which were consistent with our earlier study validating 3-AP-mediated signals by EPR, provide valuable insights into the in vivo mechanism of action of 3-AP.

Entities:  

Year:  2011        PMID: 21373381      PMCID: PMC3046871          DOI: 10.3892/etm.2010.165

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  25 in total

1.  Cytochrome c release from mitochondria: all or nothing.

Authors:  J C Martinou; S Desagher; B Antonsson
Journal:  Nat Cell Biol       Date:  2000-03       Impact factor: 28.824

2.  Three-dimensional structure of the free radical protein of ribonucleotide reductase.

Authors:  P Nordlund; B M Sjöberg; H Eklund
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

3.  Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone.

Authors:  R C DeConti; B R Toftness; K C Agrawal; R Tomchick; J A Mead; J R Bertino; A C Sartorelli; W A Creasey
Journal:  Cancer Res       Date:  1972-07       Impact factor: 12.701

4.  Mechanism of inhibition of ribonucleoside diphosphate reductase by a-(N)-heterocyclic aldehyde thiosemicarbazones.

Authors:  A C Sartorelli; K C Agrawal; E C Moore
Journal:  Biochem Pharmacol       Date:  1971-11       Impact factor: 5.858

Review 5.  Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.

Authors:  Yu Yu; Jacky Wong; David B Lovejoy; Danuta S Kalinowski; Des R Richardson
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

6.  Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems.

Authors:  W Antholine; J Knight; H Whelan; D H Petering
Journal:  Mol Pharmacol       Date:  1977-01       Impact factor: 4.436

7.  Interaction of 2-formylpyridine thiosemicarbazonato copper (II) with Ehrlich ascites tumor cells.

Authors:  L A Saryan; K Mailer; C Krishnamurti; W Antholine; D H Petering
Journal:  Biochem Pharmacol       Date:  1981-06-15       Impact factor: 5.858

8.  A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.

Authors:  Anne M Traynor; Ju-Whei Lee; Gerald K Bayer; John M Tate; Sachdev P Thomas; Miroslaw Mazurczak; David L Graham; Jill M Kolesar; Joan H Schiller
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

9.  Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase.

Authors:  Lijun Zhu; Bingsen Zhou; Xinhuan Chen; Hongjuan Jiang; Jimin Shao; Yun Yen
Journal:  Biochem Pharmacol       Date:  2009-07-02       Impact factor: 5.858

10.  Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex.

Authors:  Christian R Kowol; Robert Trondl; Vladimir B Arion; Michael A Jakupec; Irene Lichtscheidl; Bernhard K Keppler
Journal:  Dalton Trans       Date:  2009-10-22       Impact factor: 4.390

View more
  2 in total

Review 1.  Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.

Authors:  Christopher R Chitambar; William E Antholine
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

2.  Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy.

Authors:  Sanath R Wijerathna; Md Faiz Ahmad; Hai Xu; James W Fairman; Andrew Zhang; Prem Singh Kaushal; Qun Wan; Jianying Kiser; Chris G Dealwis
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.